CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
52 hedge funds and large institutions have $32.9M invested in CASI Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 11 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.01% more ownership
Funds ownership: 1.2% → 1.2% (+0.01%)
4% less funds holding
Funds holding: 54 → 52 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
28% less capital invested
Capital invested by funds: $45.9M → $32.9M (-$13M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$406K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$176K |
| 3 |
WSC
Wellington Shields & Co
New York
|
+$160K |
| 4 |
Renaissance Technologies
New York
|
+$146K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$137K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
51
Ladenburg Thalmann Financial Services
Miami,
Florida
| $6K | – | – | – |
|
|
JPLA
52
Joseph P. Lucia & Associates
Yorktown Heights,
New York
| $1 | – | – | – |
|
|
RJFSA
53
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$242K | -6,009 | Closed |
|
|
MIM
54
MetLife Investment Management
Whippany,
New Jersey
| – | -$106K | -2,632 | Closed |
|
55
Citadel Advisors
Miami,
Florida
| – | -$91K | -2,253 | Closed |
|
|
MLICM
56
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$76.2K | -1,895 | Closed |
|
57
Invesco
Atlanta,
Georgia
| – | -$53K | -1,330 | Closed |
|
|
MAM
58
Meeder Asset Management
Dublin,
Ohio
| – | -$38K | -958 | Closed |
|
|
SO
59
STRS Ohio
Columbus,
Ohio
| – | -$20K | -510 | Closed |
|
60
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -70 | Closed |
|
CASI Hedge Fund Activity: Q1 2019 in Review
52 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2019, worth a combined $32.9M — down 28% from $45.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CASI and 9 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 16 added.
The largest buyer was Vanguard Group, adding an estimated $406K. The largest seller was BlackRock, cutting an estimated $344K.
- 52 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2019, down from 54 in Q4 2018.
- Funds reported $32.9M of CASI Pharmaceuticals stock for Q1 2019, down 28% quarter-over-quarter.
- 9 funds opened new CASI Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of -2 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $406K added.
- The largest CASI Pharmaceuticals seller in Q1 2019 was BlackRock, an estimated $344K sold.
Based on aggregated 13F filings for Q1 2019.